Amryt Pharma Share Discussion Threads

[papillon] 07/3/2017 14:45

Just change the tt's to TT's otherwise advfn block the link.

[icebreaker] 07/3/2017 12:09

I am not sure whether this link has ever been posted, but it does concern our product (Lojuxta) and the potential problems we may have selling it into the EU market.

Would be interested to hear any views:

hxxp://www.fiercebiotech.com/biotech/more-woe-for-aegerion-as-ax-swings-again-withdraws-juxtapid-from-eu

[papillon] 07/3/2017 11:23

mr hangman7 Mar '17 - 10:33 - 867 of 869 0 0
"HotStockRockets" enough said...

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

mr hangman? "enough said" LOL.

PS. I just posted what was on the ShareProphets site as I thought it would be of interest. I do not subscribe to HSR for tips, nor do I know of their success (or failure!) rate. Their success rate might be very low for all I know; perhaps you would know mr hangman?

All I know about AMYT is the calibre of the BoD and executive Directors, the potential of their drug(s) and the confidence of the EIB expressed in the company by the 20m EURO funding facility. Perhaps you have contrary information that I should be made aware of, mr hangman. If so could you please post it. I'm always receptive to contrary viewpoints.

PPS. Unless you come up with some well thought out opinions I will have to filter you, mr hangman.

[bigwavedave] 07/3/2017 11:05

Published on 6 Mar 2017
Amryt Pharma PLC (LON:AMYT) chief executive Joe Wiley tells Proactive they'll soon begin a phase III clinical trial on a drug for people with a rare skin disorder following the completion of discussions with the US Food & Drug Administration and European Medicines Agency over the design of the study.

[cpap man] 07/3/2017 10:40

Amryt Pharma (AMYT.L, 19.00p) – Speculative Buy

The pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, yesterday announced the completion of discussions with the Food and Drug Administration (‘FDA’) and European Medicines Agency (‘EMA’) regarding the design of its pivotal phase 3 clinical trial for AP101. This molecule is a potential treatment for Epidermolysis Bullosa (‘EB’). EB is a rare genetic skin disorder that leads to exceptionally fragile skin and children with the disorder are often referred to as “Butterfly Children”. The global market for a treatment in EB is estimated to be in excess of EUR 1.3 billion. With regulatory authority discussions now completed with FDA and EMA and the design of the clinical trial established, Amryt is on track to commence the phase 3 trial at the end of March. Amryt has also agreed to conduct some further non-clinical studies in parallel with this phase 3 study. INC Research has been appointed as the contract research organisation for the phase 3 study, and approximately 30 clinical trial sites in 15 countries have already been pre-qualified. Adult and paediatric patients with EB will be enrolled into a randomised double blind placebo controlled trial. A total of 164 evaluable patients will be treated for a 90-day blinded period. The proportion of patients with completely healed target wounds within 45 days will be evaluated as the primary endpoint. Secondary endpoints include the time to achieve wound healing and changes in pain and pruritus (or itch). An important component of the phase 3 study is an independent data monitoring committee that will conduct an un-blinded interim efficacy analysis after 50% enrolment. The potential outcomes of this interim analysis include continuation of the study unchanged, discontinuation of the study for futility, or an increase in the number of patients in the study to preserve adequate statistical power.

Our view: This is very positive news! Reaching this critical development milestone is an important step forward for Amryt. AP101 received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. But agreement with the regulatory authorities for its phase 3 study in EB was a precursor to commencing its pivotal study, which it now expect will enrol its first patients in the coming weeks. There remains substantial unmet need for drugs which can address the symptoms and significant progress can now be made toward a potential treatment this review. Working with INC Research, Amryt believes an adaptive approach to study sample size will help to ensure that it achieves a reliable assessment of the potential benefit of this new skin healing treatment for the orphan designated disease. Having patent grants in the US and in Europe, as well as other territories including Japan, Canada and Australia, the Board estimates its global EB market opportunity to be in excess of EUR 1.3 billion. Amryt's other earlier stage product, AP102, is focused on developing novel, next generation somatostatin analogue peptide medicines for patients with rare neuroendocrine diseases, where there is also a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA. While it is true that the London equity markets have few other ‘rare diseases’ focussed development groups against which Amryt might be compared, the clear tax and development advantages offered has created a complete sub-sector of such companies listed on the US’s NASDAQ. Elementary comparison amongst these of their respective clinical development suggests a significant and unwarranted valuation gap. Beaufort retains its Speculative Buy recommendation on Amryt Pharma plc.

[papillon] 07/3/2017 09:13

We must face the fact that most (perhaps nearly all!) AIM floated O&G & biotechs turn out to be complete dross! However every now and again a diamond, such as COVE, is unearthed. Will AMYT turn out to be a diamond like COVE, or just another piece of dross like FAST? The odds are still against AMYT turning out to be a diamond, IMO, but it's a gamble I'm willing to take as I think the company is going about things in the right way. The European Investment Bank must also be happy with the company otherwise they wouldn't have made the 20m EURO facility available to AMYT. That is a vote of confidence in the company and BoD.

Unlike with FAST, the AMYT share price has yet to be subject to the hype and euphoria that often happens to AIM shares after the initial placing and listing. If I remember correctly the FAST share price was over 3 X the initial placing price at one time before drill results were received. That has never happened to AMYT. The share price is still at a discount to the original placing price.

[ny boy] 06/3/2017 19:46

Papillon, agreed, add ihavenoclue to that list, he's started stalking me again, probably be on here soon.

[papillon] 06/3/2017 19:36

Look back at mr hangman's past posts. He posts infrequently and always negatively. Unfortunately AIM is choke full of speculative no hoper companies and, in some cases, downright frauds! I don't think AMYT comes into either of those categories. However I don't need mr hangman to tell me that AMYT is still a speculative gamble! I'm betting it will come good! I'm prepared to take the risk!

"The EB market in the US and Europe is estimated to be worth c. US$1.5 billion per annum." mr hangman thinks that's a small amount of cash. Is mr hangman Warren Buffet? LOL.

Go hang out somewhere else, mr hangman!

[jacksonpollack] 06/3/2017 16:07

Look at the share price go, not.

[mr hangman] 06/3/2017 15:58

Dear me buying into an exploration co, where there is more cash then the mkt cap,
as if they every return the cash to shareholders, this is the same as FAST they
chased small anounts of oil, the new company is chasing small amounts of cash, in
the form of orphan drugs.

[papillon] 06/3/2017 15:22

It's basically a different company, in a different field, with a different BoD! FAST was a O&G hopeful whereas AMYT is a biopharma hopeful! Hopefully AMYT will be much more successful in it's field than FAST was in it's! FINGERS CROSSED. AMYT is a gamble so I've only invested what I can afford to lose, but looking at the calibre of it's BoD it's a gamble I believe could come good! However as with all speculative AIM shares it's FINGERS CROSSED! One thing I don't do is ramp shares. However, unlike CTAG, the BoD is top quality and they have a potential money spinner. However it's still FINGERS CROSSED. No one can predict the future!

I only bought into FAST when the Mkt Cap was below it's cash balance so I'm fairly happy at this moment in time.

[mr hangman] 06/3/2017 12:18

What just like Fastnet

[ny boy] 06/3/2017 10:46

Just checked the chart technicals, resistance at 20p but once clear of this and 20p becomes support, we could be due a substantive move higher as next resistance is 194p!

Hopefully the nice straight lines up long forward.

[ny boy] 06/3/2017 10:42

Hope not this early but depends at what price?

[alphabravo321] 06/3/2017 09:10

In my view as long as the share price is low we are a target for a buyout, only a question of time

[ny boy] 06/3/2017 07:40

Great news on AP101!

[icebreaker] 06/3/2017 07:23

RNS - all going to plan!

[papillon] 01/3/2017 13:00

gnnmartin. Many thanks for your interesting post. The AMYT chart is starting to look much better after yesterdays eight single share trades. Lets hope they were a good omen for the future.

[gnnmartin] 01/3/2017 11:37

papillon, I've long ben intrigued by strange reported trades: trades of 1 share being the obvious example. Having read Flash Boys, I wonder if it is automatic trading software, though I don't really expect bots to be interested in small cap shares: at least, the bots that Flash Boys talks about were (IIUC) only interested in shares that trade in five figure dollar amounts.

The starting point for designing a bot program is much like chart based trading: look at the recent trades and decide which way the share price is going to move, but whereas the chartist is interested in movement over the next days to months the bot is interested in movement over the next seconds to minutes. In the case of Flash Boys, the bot is interested in the movement over the next few microseconds.

However, pseudo charting is just the starting point. Much like the game of 'paper, scissors, stone', or indeed like poker, the bot hopes to work out what other traders intend to do by studying what they have recently done. Naturally, bots will then take steps to ensure that other bots (and human traders) don't twig what the bot intends, or even are positively misled as to the bots intentions. Humans can do the same: as did that guy from London who made millions trading on Nasdaq and has just lost his fight to avoid extradition to the USA where he faces charges of distorting the market. The moral is that it is dangerous to make too much money on the USA market even if you are only using the same trading techniques as the big boys are using in the USA. In the USA (metaphorically speaking) poker games often end in gun fights.

So, why the single share trades? Obviously this has to be done by a bot (or person) that pays millipence per trade, which rules out me! But I guess that there are some bots that look at the number of trades in the last hour (say), or look at the average price of the last 5 deals (again, I'm trying to imagine something fairly believable, nothing more accurate than that). In this case the bot that is placing the single share trades reckons that some other bot or bots might be interested in that security and wants to 'paint a picture' (as Tom Wolfe put it, in Bonfire of the Vanities). The pictures are not necessarily only aimed at other bots. People tend to look at closing prices and the movement reported during the day, or at some automatic report of closing/opening/current price, and the various media use different ways of reporting. You have probably noticed that ADVFN, LSE, III, and other can sometimes report quite different data for closing prices, current movement, and so forth. A bot that posts 5 trades of one share might be aimed at influencing one or more of these data channels. It's a bit like the ways that city boys nudged the LIBOR (etc.) rates by reporting phoney interest in loans. As ever, the line between clever negotiating and dishonest trading is blurred, and the clever negotiator who is too successful is liable to find him (or her) self described as dishonest.

One oddity that blossomed recently is the reported trade that is deleted and then immediately re-instated. For example, a trade of £10,000 at 10p per share might be deleted and immediately re-instated some hours or even a day later, by which time 10p lies well outside the current quoted spread. The honest reason for deleting and reinstating a trade is that you failed to mention that there were bargain conditions attached (say), or you got the bargain price wrong, or the quantity, or such like, but in almost all, perhaps all, examples I have noticed, the trade deleted is then reposted without any change. I notice that some media channels report the number of shares traded and fail to count a deleted trade as positive. If (for example) 100,000 shares are reported as traded at 10p at 8:00, and then at 12:00 it is reported that at 8:00 100,000 shares were wrongly marked as traded at 10p, and then at 12:01 it is reported that at 8:00 100,000 shares were traded at 10p, then some data streams add 300,000 shares to their tally of trades during the day, giving a false impression of trading activity. I expect too that some people (or bots) will get a false impression of the current share price when a big trade is posted at what is in effect an old price.

I could go on, but I guess that is more than enough for something fairly off thread. All guesswork.

[ny boy] 01/3/2017 10:10

Not long before the next leg up, same action as KMK, takes time, patience required. Will add more later

[papillon] 28/2/2017 18:59

There were EIGHT x ONE share trades today. These single share trades started at 11.50am and continued throughout the afternoon with the last one at 4.12pm. I've never, ever, seen anything like that before. Very, very, odd. The reason for this very strange (probably unique) trading pattern? NO IDEA!

I'm not surprised at todays low volume, Buffy. There were 25 trades altogether and EIGHT of those totalled just EIGHT shares!

[buffythebuffoon] 28/2/2017 15:01

All sells today, but tiny volume. I'm guessing nothing...

Buffy